Cagrilintide

Cagrilintide – Long-Acting Amylin Analogue

At a Glance: Cagrilintide is a synthetic, long-acting analogue of the naturally occurring pancreatic hormone amylin. What it is used for: It is utilized in advanced laboratory research to study profound weight loss, satiety (appetite regulation), and energy expenditure. In animal models, researchers often study it independently or in synergy with GLP-1 agonists (such as semaglutide) to observe exponential reductions in food intake and fat mass without the use of central nervous system stimulants.

Product Overview

Cagrilintide is a highly stable, next-generation research peptide designed to mimic natural amylin, a hormone co-secreted with insulin by pancreatic beta cells. While endogenous amylin has a very short half-life, Cagrilintide has been meticulously modified with a C20 fatty diacid and a stabilizing disulfide bridge. This structural modification allows it to bind heavily to circulating albumin, dramatically extending its biological action profile. By targeting both amylin and calcitonin receptors, it represents a vital compound for researching the neurobiology of satiety, allowing researchers to observe how stimulating the brain's homeostatic and hedonic regions can profoundly suppress appetite and drive lipolysis (fat breakdown) in metabolically stressed or obese lab rat models.

Technical Specifications

• Molecular Formula: C194H312N54O59S2

• CAS Number: 1415456-99-3

• Sequence Profile: 37-amino acid acylated amylin analogue featuring an N-terminal Eicosanedioic acid-γ-Glu modification and a localized Cys3-Cys8 disulfide bridge.

Mechanism of Action

Cagrilintide exerts its metabolic and behavioral effects by targeting distinct G-protein coupled receptors across the central nervous system and digestive tract:

• Non-Selective Amylin Receptor (AMYR) Agonism: Strongly binds to amylin receptors in the hindbrain and hypothalamus. This directly triggers intense neurological signals of fullness (satiety) and drastically reduces the drive for food intake.

• Calcitonin Receptor (CTR) Agonism: Activates calcitonin receptors, which further complements appetite suppression and modulates systemic energy homeostasis.

• Gastric Emptying Modulation: Significantly slows the rate at which the stomach empties its contents into the small intestine, physically prolonging the sensation of fullness and blunting post-meal blood sugar spikes.

• Glucagon Suppression: Signals the pancreas to reduce the secretion of glucagon, preventing the liver from releasing unnecessary stored glucose into the bloodstream.

Primary Research Applications

Cagrilintide is a vital compound for in vitro and animal model studies focusing on:

• Diet-induced obesity (DIO) and non-stimulant fat mass reduction

• Synergistic metabolic therapies (specifically combination studies with GLP-1 agonists)

• The neurobiology of satiety, hedonic eating, and appetite suppression

• Type 2 Diabetes, glycemic control, and delayed gastric emptying pathways

Storage & Handling

For optimal stability and structural integrity, store the lyophilized powder at -4°F (-20°C). Once reconstituted, store at 36°F to 46°F (2°C to 8°C), sealed tightly, and strictly protect from moisture and light.

⚠️ Important Disclaimer for Carbon Nova Labs Customers: All information provided is for educational and reference purposes only. Cagrilintide is sold strictly for laboratory research use only. This compound is not approved by the FDA for human consumption, therapeutic use, or clinical application.Ensure compliance with all institutional safety protocols and consult qualified professionals before conducting research.